Independent association of history of diabetic foot with all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study.

All-cause mortality Amputation Diabetic foot Foot ulcer Lower limb revascularization Type 2 diabetes

Journal

Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637

Informations de publication

Date de publication:
13 Jan 2024
Historique:
received: 13 11 2023
accepted: 28 12 2023
medline: 14 1 2024
pubmed: 14 1 2024
entrez: 13 1 2024
Statut: epublish

Résumé

Foot ulcers and/or infections are common long-term complications of diabetes and are associated with increased mortality, especially from cardiovascular disease, though only a few studies have investigated the independent contribution of these events to risk of death. This study aimed at assessing the association of history of diabetic foot with all-cause mortality in individuals with type 2 diabetes, independent of cardiovascular risk factors, other complications, and comorbidities. This prospective cohort study enrolled 15,773 Caucasian patients in 19 Italian centers in the years 2006-2008. Prior lower extremity, coronary, and cerebrovascular events and major comorbidities were ascertained by medical records, diabetic retinopathy by fundoscopy, diabetic kidney disease by albuminuria and estimated glomerular filtration rate, cardiovascular risk factors by standard methods. All-cause mortality was retrieved for 15,656 patients on 31 October 2015. At baseline, 892 patients (5.7%) had a history of diabetic foot, including ulcer/gangrene and/or amputation (n = 565; 3.58%), with (n = 126; 0.80%) or without (n = 439; 2.78%) lower limb revascularization, and revascularization alone (n = 330; 2.09%). History of diabetic foot was associated with all-cause death over a 7.42-year follow-up (adjusted hazard ratio, 1.502 [95% confidence interval, 1.346-1.676], p < 0.0001), independent of confounders, among which age, male sex, smoking, hemoglobin A In patients with type 2 diabetes, an history of diabetic foot event, including ulcer/gangrene, amputation, and lower limb revascularization, was associated with a ~ 50% increased risk of subsequent death, independent of cardiovascular risk factors, other complications and severe comorbidities, which were also significantly associated with mortality. The association with mortality was greatest for amputation, whereas that for revascularization alone was relatively modest. ClinicalTrials.gov, NCT00715481, retrospectively registered 15 July, 2008.

Sections du résumé

BACKGROUND BACKGROUND
Foot ulcers and/or infections are common long-term complications of diabetes and are associated with increased mortality, especially from cardiovascular disease, though only a few studies have investigated the independent contribution of these events to risk of death. This study aimed at assessing the association of history of diabetic foot with all-cause mortality in individuals with type 2 diabetes, independent of cardiovascular risk factors, other complications, and comorbidities.
METHODS METHODS
This prospective cohort study enrolled 15,773 Caucasian patients in 19 Italian centers in the years 2006-2008. Prior lower extremity, coronary, and cerebrovascular events and major comorbidities were ascertained by medical records, diabetic retinopathy by fundoscopy, diabetic kidney disease by albuminuria and estimated glomerular filtration rate, cardiovascular risk factors by standard methods. All-cause mortality was retrieved for 15,656 patients on 31 October 2015.
RESULTS RESULTS
At baseline, 892 patients (5.7%) had a history of diabetic foot, including ulcer/gangrene and/or amputation (n = 565; 3.58%), with (n = 126; 0.80%) or without (n = 439; 2.78%) lower limb revascularization, and revascularization alone (n = 330; 2.09%). History of diabetic foot was associated with all-cause death over a 7.42-year follow-up (adjusted hazard ratio, 1.502 [95% confidence interval, 1.346-1.676], p < 0.0001), independent of confounders, among which age, male sex, smoking, hemoglobin A
CONCLUSIONS CONCLUSIONS
In patients with type 2 diabetes, an history of diabetic foot event, including ulcer/gangrene, amputation, and lower limb revascularization, was associated with a ~ 50% increased risk of subsequent death, independent of cardiovascular risk factors, other complications and severe comorbidities, which were also significantly associated with mortality. The association with mortality was greatest for amputation, whereas that for revascularization alone was relatively modest.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov, NCT00715481, retrospectively registered 15 July, 2008.

Identifiants

pubmed: 38218843
doi: 10.1186/s12933-023-02107-9
pii: 10.1186/s12933-023-02107-9
doi:

Banques de données

ClinicalTrials.gov
['NCT00715481']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

34

Subventions

Organisme : Fondazione Diabete Ricerca
ID : NA
Organisme : Fondazione Diabete Ricerca
ID : NA
Organisme : Fondazione Diabete Ricerca
ID : NA
Organisme : Fondazione Diabete Ricerca
ID : NA
Organisme : Fondazione Diabete Ricerca
ID : NA
Organisme : Fondazione Diabete Ricerca
ID : NA
Organisme : Fondazione Diabete Ricerca
ID : NA
Organisme : Fondazione Diabete Ricerca
ID : NA
Organisme : Fondazione Diabete Ricerca
ID : NA
Organisme : Fondazione Diabete Ricerca
ID : NA
Organisme : Fondazione Diabete Ricerca
ID : NA
Organisme : Diabetes, Endocrinology and Metabolism Foundation
ID : NA
Organisme : Diabetes, Endocrinology and Metabolism Foundation
ID : NA
Organisme : Diabetes, Endocrinology and Metabolism Foundation
ID : NA
Organisme : Diabetes, Endocrinology and Metabolism Foundation
ID : NA
Organisme : Diabetes, Endocrinology and Metabolism Foundation
ID : NA
Organisme : Diabetes, Endocrinology and Metabolism Foundation
ID : NA
Organisme : Diabetes, Endocrinology and Metabolism Foundation
ID : NA
Organisme : Diabetes, Endocrinology and Metabolism Foundation
ID : NA
Organisme : Diabetes, Endocrinology and Metabolism Foundation
ID : NA
Organisme : Diabetes, Endocrinology and Metabolism Foundation
ID : NA
Organisme : Diabetes, Endocrinology and Metabolism Foundation
ID : NA
Organisme : Eli Lilly and Company
ID : NA
Organisme : Eli Lilly and Company
ID : NA
Organisme : Eli Lilly and Company
ID : NA
Organisme : Eli Lilly and Company
ID : NA
Organisme : Eli Lilly and Company
ID : NA
Organisme : Eli Lilly and Company
ID : NA
Organisme : Eli Lilly and Company
ID : NA
Organisme : Eli Lilly and Company
ID : NA
Organisme : Eli Lilly and Company
ID : NA
Organisme : Eli Lilly and Company
ID : NA
Organisme : Eli Lilly and Company
ID : NA
Organisme : Sigma-tau
ID : NA
Organisme : Sigma-tau
ID : NA
Organisme : Sigma-tau
ID : NA
Organisme : Sigma-tau
ID : NA
Organisme : Sigma-tau
ID : NA
Organisme : Sigma-tau
ID : NA
Organisme : Sigma-tau
ID : NA
Organisme : Sigma-tau
ID : NA
Organisme : Sigma-tau
ID : NA
Organisme : Sigma-tau
ID : NA
Organisme : Sigma-tau
ID : NA
Organisme : Boehringer Ingelheim
ID : NA
Organisme : Boehringer Ingelheim
ID : NA
Organisme : Boehringer Ingelheim
ID : NA
Organisme : Boehringer Ingelheim
ID : NA
Organisme : Boehringer Ingelheim
ID : NA
Organisme : Boehringer Ingelheim
ID : NA
Organisme : Boehringer Ingelheim
ID : NA
Organisme : Boehringer Ingelheim
ID : NA
Organisme : Boehringer Ingelheim
ID : NA
Organisme : Boehringer Ingelheim
ID : NA
Organisme : Boehringer Ingelheim
ID : NA
Organisme : Chiesi Farmaceutici
ID : NA
Organisme : Chiesi Farmaceutici
ID : NA
Organisme : Chiesi Farmaceutici
ID : NA
Organisme : Chiesi Farmaceutici
ID : NA
Organisme : Chiesi Farmaceutici
ID : NA
Organisme : Chiesi Farmaceutici
ID : NA
Organisme : Chiesi Farmaceutici
ID : NA
Organisme : Chiesi Farmaceutici
ID : NA
Organisme : Chiesi Farmaceutici
ID : NA
Organisme : Chiesi Farmaceutici
ID : NA
Organisme : Chiesi Farmaceutici
ID : NA
Organisme : Takeda Pharmaceutical Company
ID : NA
Organisme : Takeda Pharmaceutical Company
ID : NA
Organisme : Takeda Pharmaceutical Company
ID : NA
Organisme : Takeda Pharmaceutical Company
ID : NA
Organisme : Takeda Pharmaceutical Company
ID : NA
Organisme : Takeda Pharmaceutical Company
ID : NA
Organisme : Takeda Pharmaceutical Company
ID : NA
Organisme : Takeda Pharmaceutical Company
ID : NA
Organisme : Takeda Pharmaceutical Company
ID : NA
Organisme : Takeda Pharmaceutical Company
ID : NA
Organisme : Takeda Pharmaceutical Company
ID : NA

Informations de copyright

© 2024. The Author(s).

Références

Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and their recurrence. N Engl J Med. 2017;376:2367–75.
pubmed: 28614678 doi: 10.1056/NEJMra1615439
McDermott K, Fang M, Boulton AJM, Selvin E, Hicks CW. Etiology, epidemiology, and disparities in the Burden of Diabetic Foot Ulcers. Diabetes Care. 2023;46:209–21.
pubmed: 36548709 doi: 10.2337/dci22-0043
Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic Foot Ulcers: a review. JAMA. 2023;330:62–75.
pubmed: 37395769 doi: 10.1001/jama.2023.10578
Richard JL, Sotto A, Lavigne JP. New insights in diabetic foot Infection. World J Diabetes. 2011;2:24–32.
pubmed: 21537457 pmcid: 3083903 doi: 10.4239/wjd.v2.i2.24
Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, et al. Changes in diabetes-related Complications in the United States, 1990–2010. N Engl J Med. 2014;370:1514–23.
pubmed: 24738668 doi: 10.1056/NEJMoa1310799
Gregg EW, Hora I, Benoit SR. Resurgence in diabetes-related Complications. JAMA. 2019;321:1867–8.
pubmed: 30985875 doi: 10.1001/jama.2019.3471
Dietrich I, Braga GA, de Melo FG, da Costa Silva Silva ACC. The Diabetic Foot as a Proxy for Cardiovascular events and Mortality Review. Curr Atheroscler Rep. 2017;19:44.
pubmed: 28971322 doi: 10.1007/s11883-017-0680-z
Brownrigg JR, Davey J, Holt PJ, Davis WA, Thompson MM, Ray KK, et al. The association of ulceration of the foot with cardiovascular and all-cause mortality in patients with Diabetes: a meta-analysis. Diabetologia. 2012;55:2906–12.
pubmed: 22890823 doi: 10.1007/s00125-012-2673-3
Chammas NK, Hill RL, Edmonds ME. Increased mortality in Diabetic Foot Ulcer patients: the significance of Ulcer Type. J Diabetes Res. 2016;2016:2879809.
pubmed: 27213157 pmcid: 4860228 doi: 10.1155/2016/2879809
Stedman M, Robinson A, Dunn G, Meza-Torres B, Gibson JM, Reeves ND et al. Diabetes foot Complications and standardized mortality rate in type 2 Diabetes. Diabetes Obes Metab 2023 Sep 18.
Saluja S, Anderson SG, Hambleton I, Shoo H, Livingston M, Jude EB, et al. Foot ulceration and its association with mortality in Diabetes Mellitus: a meta-analysis. Diabet Med. 2020;37:211–8.
pubmed: 31613404 doi: 10.1111/dme.14151
Chen L, Sun S, Gao Y, Ran X. Global mortality of diabetic foot Ulcer: a systematic review and meta-analysis of observational studies. Diabetes Obes Metab. 2023;25:36–45.
pubmed: 36054820 doi: 10.1111/dom.14840
Morbach S, Furchert H, Gröblinghoff U, et al. Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade. Diabetes Care. 2012;35:2021–7.
pubmed: 22815299 pmcid: 3447849 doi: 10.2337/dc12-0200
Jupiter DC, Thorud JC, Buckley CJ, Shibuya N. The impact of foot ulceration and amputation on mortality in diabetic patients. I: from ulceration to death, a systematic review. Int Wound J. 2016;13:892–903.
pubmed: 25601358 doi: 10.1111/iwj.12404
Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care. 2003;26:491–4.
pubmed: 12547887 doi: 10.2337/diacare.26.2.491
Young MJ, McCardle JE, Randall LE, Barclay JI. Improved survival of diabetic foot Ulcer patients 1995–2008: possible impact of aggressive cardiovascular risk management. Diabetes Care. 2008;31:2143–7.
pubmed: 18697900 pmcid: 2571064 doi: 10.2337/dc08-1242
Costa RHR, Cardoso NA, Procópio RJ, Navarro TP, Dardik A, de Loiola Cisneros L. Diabetic foot Ulcer carries high amputation and mortality rates, particularly in the presence of advanced age, peripheral artery Disease and anemia. Diabetes Metab Syndr. 2017;11(Suppl 2):583–S587.
doi: 10.1016/j.dsx.2017.04.008
Amadou C, Carlier A, Amouyal C, Bourron O, Aubert C, Couture T, et al. Five-year mortality in patients with diabetic foot Ulcer during 2009–2010 was lower than expected. Diabetes Metab. 2020;46:230–5.
pubmed: 31400509 doi: 10.1016/j.diabet.2019.04.010
Jeyaraman K, Berhane T, Hamilton M, Chandra AP, Falhammar H. Mortality in patients with diabetic foot Ulcer: a retrospective study of 513 cases from a single centre in the Northern Territory of Australia. BMC Endocr Disord. 2019;19:1.
pubmed: 30606164 pmcid: 6318899 doi: 10.1186/s12902-018-0327-2
Iversen MM, Tell GS, Riise T, Hanestad BR, Østbye T, Graue M, et al. History of foot Ulcer increases mortality among individuals with Diabetes: ten-year follow-up of the Nord-Trøndelag Health Study, Norway. Diabetes Care. 2009;32:2193–9.
pubmed: 19729524 pmcid: 2782976 doi: 10.2337/dc09-0651
Lynar SA, Robinson CH, Boutlis CS, Commons RJ. Risk factors for mortality in patients with diabetic foot Infections: a prospective cohort study. Intern Med J. 2019;49:867–73.
pubmed: 30515957 doi: 10.1111/imj.14184
Mader JK, Haas W, Aberer F, Boulgaropoulos B, Baumann P, Pandis M, et al. Patients with healed diabetic foot Ulcer represent a cohort at highest risk for future fatal events. Sci Rep. 2019;9:10325.
pubmed: 31316149 pmcid: 6637072 doi: 10.1038/s41598-019-46961-8
Martins-Mendes D, Monteiro-Soares M, Boyko EJ, Ribeiro M, Barata P, Lima J, et al. The Independent contribution of diabetic foot Ulcer on lower extremity amputation and mortality risk. J Diabetes Complications. 2014;28:632–8.
pubmed: 24877985 pmcid: 4240944 doi: 10.1016/j.jdiacomp.2014.04.011
Rubio JA, Jiménez S, Lázaro-Martínez JL. Mortality in patients with Diabetic Foot Ulcers: causes, risk factors, and their association with evolution and severity of Ulcer. J Clin Med. 2020;9:3009.
pubmed: 32961974 pmcid: 7565534 doi: 10.3390/jcm9093009
Boyko EJ, Ahroni JH, Smith DG, Davignon D. Increased mortality associated with diabetic foot Ulcer. Diabet Med. 1996;13:967–72.
pubmed: 8946155 doi: 10.1002/(SICI)1096-9136(199611)13:11<967::AID-DIA266>3.0.CO;2-K
Walsh JW, Hoffstad OJ, Sullivan MO, Margolis DJ. Association of diabetic foot Ulcer and death in a population-based cohort from the United Kingdom. Diabet Med. 2016;33:1493–8.
pubmed: 26666583 doi: 10.1111/dme.13054
Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, et al. Clinical significance of nonalbuminuric renal impairment in type 2 Diabetes. J Hypertens. 2011;29:1802–9.
pubmed: 21738053 doi: 10.1097/HJH.0b013e3283495cd6
Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Arosio M, et al. Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 Diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Diabetes Care. 2012;35:143–9.
pubmed: 22124714 doi: 10.2337/dc11-1380
Pugliese G, Solini A, Fondelli C, Trevisan R, Vedovato M, Nicolucci A, et al. Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal Insufficiency and Cardiovascular events (RIACE) study. Nephrol Dial Transplant. 2011;26:3950–4.
pubmed: 21441399 doi: 10.1093/ndt/gfr140
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
pubmed: 19414839 pmcid: 2763564 doi: 10.7326/0003-4819-150-9-200905050-00006
Penno G, Solini A, Orsi E, Bonora E, Fondelli C, Trevisan R, et al. Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 Diabetes: the Renal Insufficiency and Cardiovascular events (RIACE) Italian multicentre study. Diabetologia. 2018;61:2277–89.
pubmed: 30032426 doi: 10.1007/s00125-018-4691-2
Orsi E, Solini A, Bonora E, Vitale M, Garofolo M, Fondelli C, et al. Retinopathy as an Independent predictor of all-cause mortality in individuals with type 2 Diabetes. Diabetes Metab. 2023;49:101413.
pubmed: 36460217 doi: 10.1016/j.diabet.2022.101413
Orsi E, Solini A, Bonora E, Fondelli C, Trevisan R, Vedovato M, et al. Haemoglobin A1c variability is a strong, Independent predictor of all-cause mortality in patients with type 2 Diabetes. Diabetes Obes Metab. 2018;20:1885–93.
pubmed: 29582548 doi: 10.1111/dom.13306
Penno G, Solini A, Bonora E, Orsi E, Fondelli C, Zerbini G, et al. Defining the contribution of chronic Kidney Disease to all-cause mortality in patients with type 2 Diabetes: the Renal Insufficiency and Cardiovascular events (RIACE) Italian Multicenter Study. Acta Diabetol. 2018;55:603–12.
pubmed: 29574497 doi: 10.1007/s00592-018-1133-z
Qiu L, Li Y, Yang C, Mao X, Mai L, Zhu L, et al. Influence of Foot Ulceration on all-cause and Cardiovascular Mortality in Diabetic patients: a case-control study. J Wound Ostomy Continence Nurs. 2022;49:175–9.
pubmed: 35255070 doi: 10.1097/WON.0000000000000856
Sen P, Demirdal T. Evaluation of mortality risk factors in diabetic foot Infections. Int Wound J. 2020;17:880–9.
pubmed: 32196927 pmcid: 7949473 doi: 10.1111/iwj.13343
Polikandrioti M, Vasilopoulos G, Koutelekos I, Panoutsopoulos G, Gerogianni G, Alikari V, et al. Depression in diabetic foot Ulcer: Associated factors and the impact of perceived social support and anxiety on depression. Int Wound J. 2020;17:900–9.
pubmed: 32219987 pmcid: 7948719 doi: 10.1111/iwj.13348
Williams LH, Rutter CM, Katon WJ, Reiber GE, Ciechanowski P, Heckbert SR, et al. Depression and incident diabetic foot ulcers: a prospective cohort study. Am J Med. 2010;123:748–754e3.
pubmed: 20670730 pmcid: 2913143 doi: 10.1016/j.amjmed.2010.01.023
Cascini S, Agabiti N, Davoli M, Uccioli L, Meloni M, Giurato L, et al. Survival and factors predicting mortality after major and minor lower-extremity amputations among patients with Diabetes: a population-based study using health information systems. BMJ Open Diabetes Res Care. 2020;8:e001355.
pubmed: 32690575 pmcid: 7371030 doi: 10.1136/bmjdrc-2020-001355
Hurst JE, Barn R, Gibson L, Innes H, Bus SA, Kennon B, et al. Geospatial mapping and data linkage uncovers variability in outcomes of foot Disease according to multiple deprivation: a population cohort study of people with Diabetes. Diabetologia. 2020;63:659–67.
pubmed: 31848633 doi: 10.1007/s00125-019-05056-9
Brennan MB, Powell WR, Kaiksow F, Kramer J, Liu Y, Kind AJH, et al. Association of Race, ethnicity, and Rurality with Major Leg Amputation or Death among Medicare beneficiaries hospitalized with Diabetic Foot Ulcers. JAMA Netw Open. 2022;5:e228399.
pubmed: 35446395 pmcid: 9024392 doi: 10.1001/jamanetworkopen.2022.8399
Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes Mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.
pubmed: 21366474 pmcid: 4109980 doi: 10.1056/NEJMoa1008862
Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in Diabetes. J Am Soc Nephrol. 2009;20:1813–21.
pubmed: 19443635 pmcid: 2723977 doi: 10.1681/ASN.2008121270
Hoffstad O, Mitra N, Walsh J, Margolis DJ. Diabetes, lower-extremity amputation, and death. Diabetes Care. 2015;38:1852–7.
pubmed: 26203063 doi: 10.2337/dc15-0536
Orlando G, Reeves ND, Boulton AJM, Ireland A, Federici G, Federici A, et al. Sedentary behaviour is an Independent predictor of diabetic foot Ulcer development: an 8-year prospective study. Diabetes Res Clin Pract. 2021;177:108877.
pubmed: 34058300 doi: 10.1016/j.diabres.2021.108877
De Cosmo S, Rossi MC, Pellegrini F, Lucisano G, Bacci S, Gentile S, et al. Kidney dysfunction and related cardiovascular risk factors among patients with type 2 Diabetes. Nephrol Dial Transplant. 2014;29:657–62.
pubmed: 24398892 doi: 10.1093/ndt/gft506

Auteurs

Martina Vitale (M)

Department of Clinical and Molecular Medicine, "La Sapienza" University, Via di Grottarossa, Rome, 1035-1039 - 00189, Italy.

Emanuela Orsi (E)

Diabetes Unit, Fondazione IRCCS "Cà Granda - Ospedale Maggiore Policlinico", Milan, Italy.

Anna Solini (A)

Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.

Monia Garofolo (M)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Veronica Resi (V)

Diabetes Unit, Fondazione IRCCS "Cà Granda - Ospedale Maggiore Policlinico", Milan, Italy.

Enzo Bonora (E)

Division of Endocrinology, Diabetes and Metabolism, University and Hospital Trust of Verona, Verona, Italy.

Cecilia Fondelli (C)

Diabetes Unit, University of Siena, Siena, Italy.

Roberto Trevisan (R)

Endocrinology and Diabetes Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.

Monica Vedovato (M)

Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy.

Giuseppe Penno (G)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Giuseppe Pugliese (G)

Department of Clinical and Molecular Medicine, "La Sapienza" University, Via di Grottarossa, Rome, 1035-1039 - 00189, Italy. giuseppe.pugliese@uniroma1.it.

Classifications MeSH